

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Prulifloxacin is a new fluoroquinolone with indications in the treatment of urinary tract infection and acute exacerbations of chronic bronchitis[3]. Prulifloxacin is the active metabolite of ulifloxacin with a broad in vitro activity spectrum against Gram positive and negative bacteria and among fluoroquinolones has the lowest power of inducing resistance. Prulifloxacin shows a high safety profile: it is the fluoroquinolone with the lowest risk of cardiac arrhythmias for prolongation of the QT interval; the CNS(central nervous system) penetration is negligible; in women prulifloxacin does not affect the lactobacillary component of the vaginal microbiota, lowering the risk of genito-urinary tract infections[4]. In well-designed clinical trials, prulifloxacin 600 mg administered once daily for 10 days in patients with AECB (acute exacerbations of chronic bronchitis) showed good clinical and bacteriological efficacy[5]. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00392574 | Acute Gastroenteritis in Adult... 展开 >> Travelers 收起 << | Phase 3 | Completed | - | United States, Pennsylvania ... 展开 >> INC Research New Hope, Pennsylvania, United States, 18938 收起 << |
| NCT00448422 | Acute Bacterial Gastroenteriti... 展开 >>s 收起 << | Phase 3 | Completed | - | India ... 展开 >> Goa Medical College Bambolim, Goa, India 收起 << |
| NCT02130713 | Chronic Bacterial Prostatitis | Phase 4 | Completed | - | Italy ... 展开 >> policlinico Umberto I - Department of Gynecological-Obstetrics Sciences and Urological Sciences Roma, Italy, 00161 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.17mL 0.43mL 0.22mL |
10.84mL 2.17mL 1.08mL |
21.67mL 4.33mL 2.17mL |
|
| CAS号 | 123447-62-1 |
| 分子式 | C21H20FN3O6S |
| 分子量 | 461.46 |
| SMILES Code | O=C(C1=C(SC2C)N2C3=C(C=C(F)C(N4CCN(CC5=C(C)OC(O5)=O)CC4)=C3)C1=O)O |
| MDL No. | MFCD00864847 |
| 别名 | NM441; AF 3013 |
| 运输 | 蓝冰 |
| InChI Key | PWNMXPDKBYZCOO-UHFFFAOYSA-N |
| Pubchem ID | 65947 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 12 mg/mL(26 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1